According to Iridex, the IQ 577 is a high-power, true yellow laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma.
The IQ 577 offers tangible benefits to both patient and physician. Patients benefit from less discomfort. The higher inherent absorption in blood, together with the lower scattering of the 577nm yellow laser wavelength, compared with 532nm green laser systems, helps to reduce the therapeutic power requirements and resultant patient discomfort, the company said.
Theodore Boutacoff, president and CEO of Iridex, said: “These argon-pumped dye laser systems, now obsolete, were popular at one time; however, they were large, had high electrical power demands, required circulating water for cooling, and were expensive to maintain and service.
“In contrast, we have directed our company’s experience and expertise to develop the IQ 577, reintroducing this laser wavelength to clinicians in a modern product utilizing reliable and efficient solid-state laser technology.”